Replies to post #379549 on Anavex Life Sciences Corp (AVXL)

[Investor2014]

Good realistic perspective post Sokol.

I think there is good reason to believe the P2b/3 is not a flop and that A2-73 may well slow AD just as much as lacanemab (27%) with a better safety profile and oral administration. Maybe subgroup analysis will find even better signals for a follow-on Precision Medicine P3 trial.

We only have to wait a few weeks to find out with some trepidation and excitement at the same time, imo.

[plexrec]

sokol--"significantly, success has been achieved."--good post --thanks for sharing podcast info !!!!